{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:26:14Z","timestamp":1785291974305,"version":"3.55.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["MGS\/2021\/15"],"award-info":[{"award-number":["MGS\/2021\/15"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Spanish Scientific Research Council","doi-asserted-by":"publisher","award":["FJC2018\u2013035791-I"],"award-info":[{"award-number":["FJC2018\u2013035791-I"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115775","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T18:54:01Z","timestamp":1699383241000},"page":"115775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-0014","authenticated-orcid":false,"given":"Francisco","family":"Madrid-Gambin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fabregat-Safont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gomez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eul\u00e0lia","family":"Olesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar J.","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115775_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2023.115775_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2023.115775_bib3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","article-title":"Psychedelics in the treatment of unipolar mood disorders: a systematic review","volume":"30","author":"Rucker","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib4","doi-asserted-by":"crossref","unstructured":"Doblin, R.E.; Christiansen, M.; Jerome, L.; Burge, B. The Past and Future of Psychedelic Science: An Introduction to This Issue. \u3008https:\/\/doi.org\/10.1080\/02791072.2019.1606472\u3009 2019, 51, 93\u201397, \u3008doi:10.1080\/02791072.2019.1606472\u3009.","DOI":"10.1080\/02791072.2019.1606472"},{"key":"10.1016\/j.biopha.2023.115775_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2021.619890","article-title":"The evolved psychology of psychedelic set and setting: inferences regarding the roles of shamanism and entheogenic ecopsychology","volume":"12","author":"Winkelman","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2023.115775_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-8741(94)90051-5","article-title":"Bufo alvarius: a potent hallucinogen of animal origin","volume":"41","author":"Weil","year":"1994","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"10.1016\/j.biopha.2023.115775_bib9","series-title":"Pihkal: A Chemical Love Story","author":"Shulgin","year":"1991"},{"key":"10.1016\/j.biopha.2023.115775_bib10","doi-asserted-by":"crossref","first-page":"11207","DOI":"10.1073\/pnas.1902174116","article-title":"Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America","volume":"166","author":"Miller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2023.115775_bib11","first-page":"1576","article-title":"2019, undefined Bufo alvarius: evidencias literarias y controversias en torno a su uso tradicional","volume":"13","author":"Hor\u00e1k","year":"2019","journal-title":"dialnet. unirioja. es"},{"key":"10.1016\/j.biopha.2023.115775_bib12","unstructured":"Schultes, R.E.; Hofmann, A. Plants of the gods: origins of hallucinogenic use; 1979; ISBN 0091416000."},{"key":"10.1016\/j.biopha.2023.115775_bib13","series-title":"Psychedelic Drugs Reconsidered","author":"Grinspoon","year":"1979"},{"key":"10.1016\/j.biopha.2023.115775_bib14","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1021\/acschemneuro.8b00043","article-title":"Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)","volume":"9","author":"Nichols","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2023.115775_bib15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2023.115775_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/ajp.108.12.896","article-title":"Lysergic acid diethylamide; a clinical-psychological study","volume":"108","author":"SAVAGE","year":"1952","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib17","first-page":"333","article-title":"Nuestra experiencia sobre el empleo del delysid y la psylocibina en el tratamiento de la neurosis obsesiva","volume":"48","author":"Mart\u00ed Granell","year":"1962","journal-title":"Ann. Med."},{"key":"10.1016\/j.biopha.2023.115775_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005053-196706000-00004","article-title":"Therapeutic effects of LSD: a follow-up study","volume":"144","author":"Shagass","year":"1967","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.biopha.2023.115775_bib19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.biopha.2023.115775_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","article-title":"Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning","volume":"228","author":"Catlow","year":"2013","journal-title":"Exp. brain Res."},{"key":"10.1016\/j.biopha.2023.115775_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2023.115775_bib22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"de Vos","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","article-title":"Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years","volume":"6","author":"Santos","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib25","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers","volume":"78","author":"Kraehenmann","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib28","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","volume":"236","author":"Uthaug","year":"2019","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib30","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.biopha.2023.115775_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/02698811211044688","article-title":"Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis","volume":"36","author":"Leger","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib32","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","article-title":"LSD acutely impairs fear recognition and enhances emotional empathy and sociality","volume":"41","author":"Dolder","year":"2016","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.biopha.2023.115775_bib33","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3389\/fphar.2021.721537","article-title":"Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being","volume":"12","author":"Kiraga","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib34","doi-asserted-by":"crossref","unstructured":"Loizaga-Velder, A.; Verres, R. Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence\u2014Qualitative Results. \u3008https:\/\/doi.org\/10.1080\/02791072.2013.873157\u3009 2014, 46, 63\u201372, \u3008doi:10.1080\/02791072.2013.873157\u3009.","DOI":"10.1080\/02791072.2013.873157"},{"key":"10.1016\/j.biopha.2023.115775_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: a systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.biopha.2023.115775_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-019-1135-1","article-title":"Serotonin transporter\u2013ibogaine complexes illuminate mechanisms of inhibition and transport","volume":"569","author":"Coleman","year":"2019","journal-title":"Nat"},{"key":"10.1016\/j.biopha.2023.115775_bib37","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00213-018-4988-3","article-title":"Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution","volume":"235","author":"Uthaug","year":"2018","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2023.115775_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2023.115775_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF00443425","article-title":"Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex","volume":"97","author":"Pierce","year":"1989","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib43","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1021\/acschemneuro.8b00101","article-title":"Dark classics in chemical neuroscience: N, N-dimethyltryptamine (DMT)","volume":"9","author":"Cameron","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2023.115775_bib44","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0006-2952(70)90378-3","article-title":"Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism","volume":"19","author":"Freedman","year":"1970","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.biopha.2023.115775_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and \u03b2-carboline constituents of Ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-006-0358-7","article-title":"Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant","volume":"186","author":"Riba","year":"2006","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118143","article-title":"The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network","volume":"10","author":"Palhano-Fontes","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115775_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","article-title":"Is LSD toxic?","volume":"284","author":"Nichols","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.biopha.2023.115775_bib50","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","article-title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants","volume":"239","author":"M\u00fcller","year":"2022","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2023.115775_bib52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib53","first-page":"1","article-title":"The adverse events of ibogaine in humans: an updated systematic review of the literature (2015\u20132020)","volume":"1","author":"Ona","year":"2021","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib54","first-page":"1","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"2021","author":"Malcolm","year":"2021","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.biopha.2023.115775_bib55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/jpm8030028","article-title":"A metabolomics approach to pharmacotherapy personalization","volume":"Vol. 8","author":"Balashova","year":"2018","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2023.115775_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-030-21735-8_10","article-title":"Metabolomics biomarkers for precision psychiatry","volume":"1161","author":"Shih","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biopha.2023.115775_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrm.2016.25","article-title":"Metabolomics: beyond biomarkers and towards mechanisms","volume":"17","author":"Johnson","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2023.115775_bib58","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/004982599238047","article-title":"Metabonomics\u201d: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data","volume":"29","author":"Nicholson","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2023.115775_bib59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1013713905833","article-title":"Metabolomics \u2013 the link between genotypes and phenotypes","volume":"48","author":"Fiehn","year":"2002","journal-title":"Plant Mol. Biol."},{"key":"10.1016\/j.biopha.2023.115775_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.145","article-title":"Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants","volume":"6","author":"Rotroff","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib61","article-title":"Cannabis-responsive biomarkers: a pharmacometabolomics-based application to evaluate the impact of medical cannabis treatment on children with autism spectrum disorder","author":"Siani-Rose","year":"2021","journal-title":"Cannabis cannabinoid Res"},{"key":"10.1016\/j.biopha.2023.115775_bib62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib64","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1021\/acs.jproteome.7b00294","article-title":"First time view on human metabolome changes after a single intake of 3,4-methylenedioxymethamphetamine in healthy placebo-controlled subjects","volume":"16","author":"Boxler","year":"2017","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.biopha.2023.115775_bib65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/03602532.2019.1638931","article-title":"anio Metabolism of lysergic acid diethylamide (LSD): an update","volume":"51","author":"Filipe Lib\u00e2nio Os\u00f3rio Marta","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biopha.2023.115775_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib67","first-page":"2276","article-title":"1H nuclear magnetic resonance: a future approach to the metabolic profiling of psychedelics in human biofluids?","volume":"0","author":"Vilca-Melendez","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.biopha.2023.115775_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyv072","article-title":"Pharmacokinetics and concentration-effect relationship of oral LSD in humans","volume":"19","author":"Dolder","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.biopha.2023.115775_bib71","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/bcp.13918","article-title":"Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects","volume":"85","author":"Holze","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib72","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2023.115775_bib73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","article-title":"Gender effects in pharmacokinetics and pharmacodynamics","volume":"50","author":"Harris","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.115775_bib74","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1021\/js9702168","article-title":"Influence of race or ethnicity on pharmacokinetics of drugs","volume":"86","author":"Johnson","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.115775_bib75","doi-asserted-by":"crossref","unstructured":"Cascorbi, I. Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics. \u3008http:\/\/dx.doi.org\/10.2217\/pgs.13.194\u3009 2013, 14, 1807\u20131809, \u3008doi:10.2217\/PGS.13.194\u3009.","DOI":"10.2217\/pgs.13.194"},{"key":"10.1016\/j.biopha.2023.115775_bib76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003088-199937030-00003","article-title":"Effects of food on clinical pharmacokinetics","volume":"37","author":"Singh","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2023.115775_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-90343-y","article-title":"Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis","volume":"11","author":"Vizeli","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115775_bib78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","article-title":"Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use","volume":"164","author":"Luethi","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/1055-9965.EPI-12-1109","article-title":"Metabolomics in epidemiology: sources of variability in metabolite measurements and implications","volume":"22","author":"Sampson","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.biopha.2023.115775_bib81","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1096\/fj.11-198093","article-title":"The dynamic range of the human metabolome revealed by challenges","volume":"26","author":"Krug","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.115775_bib82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11306-011-0289-0","article-title":"Development and validation of a standardized protocol to monitor human dietary exposure by metabolite fingerprinting of urine samples","volume":"7","author":"Fav\u00e9","year":"2011","journal-title":"Metabolomics"},{"key":"10.1016\/j.biopha.2023.115775_bib83","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s11306-014-0746-7","article-title":"Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review","volume":"11","author":"Emwas","year":"2015","journal-title":"Metabolomics"},{"key":"10.1016\/j.biopha.2023.115775_bib84","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neubiorev.2020.09.035","article-title":"Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: a systematic review","volume":"119","author":"Ona","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.biopha.2023.115775_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/FBP.0000000000000198","article-title":"Sex differences and serotonergic mechanisms in the behavioural effects of psilocin","volume":"27","author":"Tyl\u0161","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib86","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cpt.2958","article-title":"Assessment of the Acute effects of 2C-B vs. psilocybin on subjective experience, mood, and cognition","volume":"114","author":"Mallaroni","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2023.115775_bib87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/02791072.2014.948329","article-title":"The psychedelic explorer\u2019s guide: safe, therapeutic, and sacred journeys","volume":"46","author":"Rhead","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.biopha.2023.115775_bib88","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","article-title":"The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial","volume":"236","author":"Yanakieva","year":"2019","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib89","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-food-030212-182612","article-title":"Nutrimetabonomics:applications for nutritional sciences, with specific reference to gut microbial interactions","volume":"4","author":"Claus","year":"2013","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"10.1016\/j.biopha.2023.115775_bib90","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00414-006-0078-x","article-title":"LC-ESI-MS\/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor","volume":"121","author":"Favretto","year":"2007","journal-title":"Int. J. Leg. Med."},{"key":"10.1016\/j.biopha.2023.115775_bib91","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/nprot.2007.376","article-title":"Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts","volume":"2","author":"Beckonert","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2023.115775_bib92","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nprot.2010.50","article-title":"Global metabolic profiling procedures for urine using UPLC\u2013MS","volume":"5","author":"Want","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2023.115775_bib93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0378-4347(98)00574-X","article-title":"Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD","volume":"724","author":"Poch","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.biopha.2023.115775_bib94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jat\/27.7.459","article-title":"LC-MS analysis of 2-Oxo-3-Hydroxy LSD from Urine Using a Speedisk\u00ae positive-pressure processor with cerex\u00ae polychrom\u2122 CLIN II columns.","volume":"27","author":"Horn","year":"2003","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.biopha.2023.115775_bib95","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jat\/23.5.306","article-title":"Quantitative determination of LSD and a major metabolite, 2-Oxo-3-hydroxy-LSD, in human urine by solid-phase extraction and gas chromatography-tandem mass spectrometry","volume":"23","author":"Reuschel","year":"1999","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.biopha.2023.115775_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.trac.2009.12.003","article-title":"Metabolomics analysis I. Selection of biological samples and practical aspects preceding sample preparation","volume":"29","author":"\u00c1lvarez-S\u00e1nchez","year":"2010","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.biopha.2023.115775_bib97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/metabo12010015","article-title":"Defining blood plasma and serum metabolome by gc-ms","volume":"12","author":"Kiseleva","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.biopha.2023.115775_bib98","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/0006-2952(87)90159-6","article-title":"Urinary excretion of 5-methoxy-N,N-dimethyltryptamine, N,N-dimethyltryptamine and their N-oxides in the rat","volume":"36","author":"Sitaram","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib99","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0006-2952(87)90117-1","article-title":"Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography","volume":"36","author":"Sitaram","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib100","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/bmc.1551","article-title":"Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine","volume":"25","author":"Mcilhenny","year":"2011","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2023.115775_bib101","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1039\/C1AN15605E","article-title":"Modern analytical techniques in metabolomics analysis","volume":"137","author":"Zhang","year":"2012","journal-title":"Analyst"},{"key":"10.1016\/j.biopha.2023.115775_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/ac990769y","article-title":"Direct plasma sample injection in multiple-component LC\u2212MS\u2212MS assays for high-throughput pharmacokinetic screening","volume":"72","author":"Wu","year":"1999","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2023.115775_bib103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0731-7085(02)00278-9","article-title":"Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man","volume":"30","author":"Hasler","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1570-0232(02)00397-5","article-title":"Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca","volume":"779","author":"Yritia","year":"2002","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2023.115775_bib105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.103.049882","article-title":"Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics","volume":"306","author":"Riba","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.115775_bib106","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1042\/bj0321763","article-title":"Elimination of amines in man","volume":"32","author":"Richter","year":"1938","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2023.115775_bib107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.trac.2004.11.021","article-title":"Metabolomics: current analytical platforms and methodologies","volume":"24","author":"Dunn","year":"2005","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.biopha.2023.115775_bib108","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jat\/26.4.193","article-title":"LC-MS analysis of human urine specimens for 2-Oxo-3-Hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy lsd under various storage conditions","volume":"26","author":"Klette","year":"2002","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.biopha.2023.115775_bib109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jat\/27.4.249","article-title":"The development and application of a gas chromatography-mass spectrometric (GC-MS) assay to determine the presence of 2-oxo-3-hydroxy-LSD in urine","volume":"27","author":"Burnley","year":"2003","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.biopha.2023.115775_bib110","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/ac00038a014","article-title":"Determination of lysergic acid diethylamide (LSD), iso-LSD, and N-demethyl-LSD in body fluids by gas chromatography\/tandem mass spectrometry","volume":"64","author":"Nelson","year":"1992","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2023.115775_bib111","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/ac00165a015","article-title":"Quantification of LSD and N-demethyl-LSD in urine by gas chromatography\/resonance electron capture ionization mass spectrometry","volume":"60","author":"Lim","year":"1988","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2023.115775_bib112","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/dta.2042","volume":"9","author":"Steuer","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22265","article-title":"Development and validation of an LC-MS\/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial","volume":"32","author":"Dolder","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib114","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00414-012-0796-1","article-title":"Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS\/MS","volume":"127","author":"Martin","year":"2013","journal-title":"Int. J. Leg. Med."},{"key":"10.1016\/j.biopha.2023.115775_bib115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00427703","article-title":"Metabolic fate of mescaline in man","volume":"9","author":"Charalampous","year":"1966","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.biopha.2023.115775_bib116","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0006-2952(74)90417-1","article-title":"Oxidative metabolism of mescaline in the central nervous system. 3. Side chain degradation of mescaline and formation of 3,4,5-trimethoxy-benzoic acid in vivo","volume":"23","author":"Seiler","year":"1974","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1749-6632.1962.tb50097.x","article-title":"New developments in metabolism of mescaline and related amines","volume":"96","author":"Friedhoff","year":"1962","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2023.115775_bib118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-007-0926-5","article-title":"Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose","volume":"196","author":"P\u00e1len\u00ed\u010dek","year":"2008","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib119","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000105047","article-title":"The metabolism of mescalin in the human; delayed clinical reactions to mescalin","volume":"18","author":"Harley-Mason","year":"1958","journal-title":"Confin. Neurol."},{"key":"10.1016\/j.biopha.2023.115775_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114980","article-title":"Development and validation of an LC-MS\/MS method for the quantification of mescaline and major metabolites in human plasma","volume":"220","author":"Thomann","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib121","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF00427525","article-title":"Stimulation of human prolactin secretion by mescaline","volume":"64","author":"Demisch","year":"1979","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib122","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0006-2952(80)90169-0","article-title":"Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates","volume":"29","author":"Barker","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib123","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib124","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bmc.1657","article-title":"Methodology for determining major constituents of ayahuasca and their metabolites in blood","volume":"26","author":"McIlhenny","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2023.115775_bib125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/02791072.2000.10400456","article-title":"Bufotenine: toward an understanding of possible psychoactive mechanisms","volume":"32","author":"McBride","year":"2000","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.biopha.2023.115775_bib126","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-Response Study of N,N-Dimethyltryptamine in Humans: I. Neuroendocrine, Autonomic, and Cardiovascular Effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.biopha.2023.115775_bib127","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/dta.1344","article-title":"Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca","volume":"4","author":"Riba","year":"2012","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib128","first-page":"15","article-title":"Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice","author":"Tweedie","year":"1987","journal-title":"Identif. Quant. two Nov. harmine Metab. Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115775_bib129","first-page":"174","article-title":"A Model Of Harmine Metabolism In The Rat","author":"Slotkin","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.115775_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112845","article-title":"Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience","volume":"149","author":"Madrid-Gambin","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.115775_bib131","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1208\/s12248-008-9028-5","article-title":"Indolealkylamines: Biotransformations and potential drug-drug interactions","volume":"10","author":"Yu","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2023.115775_bib132","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00213-019-05414-w","article-title":"Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment","volume":"237","author":"Uthaug","year":"2020","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib133","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib134","doi-asserted-by":"crossref","unstructured":"Dinis-Oliveira, R.J. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. \u3008http:\/\/dx.doi.org\/10.1080\/03602532.2016.1278228\u3009 2017, 49, 84\u201391, \u3008doi:10.1080\/03602532.2016.1278228\u3009.","DOI":"10.1080\/03602532.2016.1278228"},{"key":"10.1016\/j.biopha.2023.115775_bib135","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.biopha.2023.115775_bib136","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.109.031138","article-title":"Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases","volume":"38","author":"Manevski","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115775_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122486","article-title":"Development and validation of an LC-MS\/MS method for the bioanalysis of psilocybin\u2019s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma","volume":"1164","author":"Kolaczynska","year":"2021","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2023.115775_bib138","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11419-006-0006-2","article-title":"Direct detection of serum psilocin glucuronide by LC\/MS and LC\/MS\/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a \u201cmagic mushroom\u201d user","volume":"24","author":"Kamata","year":"2006","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.biopha.2023.115775_bib139","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jchromb.2003.08.030","article-title":"Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples","volume":"796","author":"Kamata","year":"2003","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.biopha.2023.115775_bib140","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/dta.3106","article-title":"Further development of a liquid chromatography\u2013high-resolution mass spectrometry\/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions","volume":"13","author":"Bambauer","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib141","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological affects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2023.115775_bib142","article-title":"Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers","volume":"2022","author":"Mason","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2023.115775_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114642","article-title":"Development and application of a highly sensitive LC-MS\/MS method for simultaneous quantification of N,N-dimethyltryptamine and two of its metabolites in human plasma","volume":"212","author":"Eckern\u00e4s","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2023.115775_bib144","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00005053-196003000-00006","article-title":"Urinary aromatic metabolites in normal subjects after LSD","volume":"130","author":"MASUDA","year":"1960","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.biopha.2023.115775_bib145","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0090-9556(25)06273-7","article-title":"3,4,5-Trimethoxybenzoic acid, a new mescaline metabolite in humans","volume":"6","author":"Demisch","year":"1978","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115775_bib146","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euroneuro.2021.06.001","article-title":"Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience","volume":"50","author":"Madsen","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2023.115775_bib147","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:14:30Z","timestamp":1777576470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223015731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":147,"alternative-id":["S0753332223015731"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115775","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115775"}}